Related references
Note: Only part of the references are listed.Patient-derived xenograft models-the future of personalised cancer treatment
Jenna Bhimani et al.
BRITISH JOURNAL OF CANCER (2020)
Cancer Genome Evolutionary Trajectories in Metastasis
Nicolai J. Birkbak et al.
CANCER CELL (2020)
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
Lillian M. Smyth et al.
CANCER DISCOVERY (2020)
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial
O. Tredan et al.
ANNALS OF ONCOLOGY (2019)
New clinical trial designs in the era of precision medicine
Elena Garralda et al.
MOLECULAR ONCOLOGY (2019)
Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma
V. Gambardella et al.
ANNALS OF ONCOLOGY (2019)
The current state of molecular testing in the treatment of patients with solid tumors, 2019
Wafik S. El-Deiry et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
A phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts).
Teresa Macarulla Mercade et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
Jason K. Sicklick et al.
NATURE MEDICINE (2019)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Jordi Rodon et al.
NATURE MEDICINE (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2019)
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas
Chia-Chi Lin et al.
BRITISH JOURNAL OF CANCER (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Andreas Weiss et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
Aparna R. Parikh et al.
NATURE MEDICINE (2019)
Phase I trials as valid therapeutic options for patients with cancer
Jacob J. Adashek et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D. Kim et al.
CANCER DISCOVERY (2019)
Breast cancer
Nadia Harbeck et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
NTRK-Fusions - A new kid on the block
Bruno Maerkl et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer
Valentina Gambardella et al.
CLINICAL CANCER RESEARCH (2019)
Is Precision Medicine an Oxymoron?
S. Gail Eckhardt et al.
JAMA ONCOLOGY (2019)
Tumour heterogeneity and resistance to cancer therapies
Ibiayi Dagogo-Jack et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition
Arlene Siefker-Radtke et al.
NATURE REVIEWS UROLOGY (2018)
NRF2 and the Hallmarks of Cancer
Montserrat Rojo de la Vega et al.
CANCER CELL (2018)
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
Rona Yaeger et al.
CANCER CELL (2018)
Revolutionizing Precision Oncology through Collaborative Proteogenomics and Data Sharing
Henry Rodriguez et al.
CELL (2018)
Establishment of a Patient-Derived Tumor Xenograft Model and Application for Precision Cancer Medicine
Seiji Okada et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2018)
The NCl-MATCH trial and precision medicine in gynecologic cancers
Lisa Barroilhet et al.
GYNECOLOGIC ONCOLOGY (2018)
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
John D. Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
Simona Soverini et al.
MOLECULAR CANCER (2018)
The emerging clinical relevance of genomics in cancer medicine
Michael F. Berger et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
The paradox of precision medicine
Jonathan Kimmelman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Georgios Vlachogiannis et al.
SCIENCE (2018)
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
Sumanta K. Pal et al.
CANCER DISCOVERY (2018)
Precision dosing in clinical medicine: present and future
Thomas M. Polasek et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2018)
MEN1611, a novel α-selective PI3K inhibitor in solid tumors
Giuseppe Merlino et al.
CANCER RESEARCH (2018)
First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US.
Kyriakos P. Papadopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC).
Christian H. H. Ottensmeier et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
David M. Hyman et al.
NATURE (2018)
Phosphatidylinositol 3-Kinase, Growth Disorders, and Cancer
Marcus D. Goncalves et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
First-in-human phase 1 study of E7090, a novel selective inhibitor of FGFRs, in patients with advanced solid tumors
Takafumi Koyama et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
Tony S. K. Mok et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
Toshihiko Doi et al.
LANCET ONCOLOGY (2017)
Functional precision cancer medicine-moving beyond pure genomics
Anthony Letai
NATURE MEDICINE (2017)
A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
Michael Michael et al.
TARGETED ONCOLOGY (2017)
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
Christophe Massard et al.
CANCER DISCOVERY (2017)
Molecular Tumor Boards: current practice and future needs
D. L. van der Velden et al.
ANNALS OF ONCOLOGY (2017)
Metabolomics Applications in Precision Medicine: An Oncological Perspective
Leonor Puchades-Carrasco et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2017)
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers
Paul K. Paik et al.
CLINICAL CANCER RESEARCH (2017)
Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future
A. S. Darwich et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina et al.
NATURE REVIEWS CANCER (2017)
Implementing Genome-Driven Oncology
David M. Hyman et al.
CELL (2017)
Emerging Biological Principles of Metastasis
Arthur W. Lambert et al.
CELL (2017)
Modeling Development and Disease with Organoids
Hans Clevers
CELL (2016)
Proteogenomics connects somatic mutations to signalling in breast cancer
Philipp Mertins et al.
NATURE (2016)
Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution
Nicholas McGranahan et al.
CANCER CELL (2015)
First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer (vol 20, pg 5908, 2014)
S. Blagden et al.
CLINICAL CANCER RESEARCH (2015)
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
Maria Schwaederle et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-Analysis of Clinical Trials Leading to FDA Approval
Denis L. Fontes Jardim et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau et al.
LANCET ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-Analysis of Clinical Trials Leading to FDA Approval
Denis L. Fontes Jardim et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
R. Dienstmann et al.
ANNALS OF ONCOLOGY (2014)
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Luminal breast cancer: from biology to treatment
Michail Ignatiadis et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
Maria Vittoria Dieci et al.
CANCER DISCOVERY (2013)
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Apostolia-Maria Tsimberidou et al.
CLINICAL CANCER RESEARCH (2012)
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Darrell R. Borger et al.
ONCOLOGIST (2012)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2011)
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Pharmaco-metabonomic phenotyping and personalized drug treatment
TA Clayton et al.
NATURE (2006)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Share Paper
